# PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan

> clinical trial · VERIFIED · 2026-08-12

Status: RECRUITING · Sponsor: AstraZeneca · Condition: Breast Neoplasms

- Company: AstraZeneca
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT05573893

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.